Soy - is the little bean back in the cardiovascular health game? Results of a study from Soy Labs, LLC confirm that it is. Lunastatin(TM) (aka Lunasin), a chromatin-binding peptide derived from soy, appears to be an active factor responsible for the LDL cholesterol-lowering effect attributed to soy protein. Alfredo F. Galvez, Ph.D., Molecular Biologist at the NCMHD Center for Excellence in Nutritional Genomics at University of California, Davis; Adjunct Assistant Professor at the University of Missouri; and the study's lead researcher, presented his findings at the Fourth International Conference on Soy and Health in Dusseldorf, Germany last week.

"These findings indicate tremendous promise for Lunastatin(TM) as a way to safely reduce cholesterol without the side effects associated with statin drugs," stated Dr. Galvez.

"Lowering cholesterol is key to maintaining heart health," stated Soy Labs President Ryan Schmidt. "While statin drugs have been somewhat effective in that area, there is broad-based concern that the risks (e.g., cancer, liver and kidney damage, etc.) outweigh the benefits. We're confident that all-natural Lunastatin(TM) holds the key to lowering cholesterol safely." Soy Labs is in the process of developing proprietary ingredients and finished products that will feature Lunastatin(TM).

The American Heart Association (AHA) earlier reported that soy protein lowers harmful LDL cholesterol by only 3 percent, contrary to the FDA health claim on soy protein. Given the available body of research, it would seem likely that the AHA is referring to a few unimpressive research studies on soy protein or isoflavones (phytoestrogen found in soy) without knowledge of the responsible nutrient for cholesterol lowering. The Soy Labs' study is different because it focused on the specific component in soy protein that is effective in reducing harmful cholesterol.